121 related articles for article (PubMed ID: 2182939)
1. Association between sympathetic activity and the atherogenic serum cholesterol fraction.
Weidmann P; Schohn DC; Riesen W; Jahn HA; Ferrari P; Shaw SG; Beretta-Piccoli C
Klin Wochenschr; 1990 Mar; 68(5):269-76. PubMed ID: 2182939
[TBL] [Abstract][Full Text] [Related]
2. Norepinephrine-related mechanism in hypertension accompanying renal failure.
Schohn D; Weidmann P; Jahn H; Beretta-Piccoli C
Kidney Int; 1985 Nov; 28(5):814-22. PubMed ID: 4087696
[TBL] [Abstract][Full Text] [Related]
3. Lipoprotein particle abnormalities and the impaired lipolysis in renal insufficiency.
Lee DM; Knight-Gibson C; Samuelsson O; Attman PO; Wang CS; Alaupovic P
Kidney Int; 2002 Jan; 61(1):209-18. PubMed ID: 11786103
[TBL] [Abstract][Full Text] [Related]
4. The utility of non-HDL in managing dyslipidemia of stage 5 chronic kidney disease.
Pennell P; Leclercq B; Delahunty MI; Walters BA
Clin Nephrol; 2006 Nov; 66(5):336-47. PubMed ID: 17140163
[TBL] [Abstract][Full Text] [Related]
5. Effects of oral taurine supplementation on lipids and sympathetic nerve tone.
Mizushima S; Nara Y; Sawamura M; Yamori Y
Adv Exp Med Biol; 1996; 403():615-22. PubMed ID: 8915402
[TBL] [Abstract][Full Text] [Related]
6. Cardiovascular counterregulation during sympathetic inhibition in normal subjects and patients with mild hypertension.
Weidmann P; Beretta-Piccoli C; Link L; Bianchetti MG; Boehringer K; Morton JJ
Hypertension; 1983; 5(6):873-80. PubMed ID: 6360870
[TBL] [Abstract][Full Text] [Related]
7. Effect of fluvastatin on intermediate density lipoprotein (remnants) and other lipoprotein levels in hypercholesterolemia.
Broyles FE; Walden CE; Hunninghake DB; Hill-Williams D; Knopp RH
Am J Cardiol; 1995 Jul; 76(2):129A-135A. PubMed ID: 7604788
[TBL] [Abstract][Full Text] [Related]
8. Lipoprotein profile in patients who survive a stroke.
Oravec S; Krivosikova Z; Krivosik M; Gruber K; Gruber M; Dukát A; Gavorník P
Neuro Endocrinol Lett; 2011; 32(4):496-501. PubMed ID: 21876499
[TBL] [Abstract][Full Text] [Related]
9. Rationale for use of non-high-density lipoprotein cholesterol rather than low-density lipoprotein cholesterol as a tool for lipoprotein cholesterol screening and assessment of risk and therapy.
Frost PH; Havel RJ
Am J Cardiol; 1998 Feb; 81(4A):26B-31B. PubMed ID: 9526810
[TBL] [Abstract][Full Text] [Related]
10. Reduction of intermediate density lipoprotein by pravastatin in hemo- and peritoneal dialysis patients.
Nishizawa Y; Shoji T; Emoto M; Kawasaki K; Konishi T; Tabata T; Inoue T; Morii H
Clin Nephrol; 1995 Apr; 43(4):268-77. PubMed ID: 7606882
[TBL] [Abstract][Full Text] [Related]
11. Correlates of serum lipids and lipoproteins in Congolese patients with arterial hypertension.
Lepira FB; M'Buyamba-Kabangu JR; Kayembe KP; Nseka MN
Cardiovasc J S Afr; 2005; 16(5):249-55. PubMed ID: 16307156
[TBL] [Abstract][Full Text] [Related]
12. Effects of fenofibrate and ezetimibe, both as monotherapy and in coadministration, on cholesterol mass within lipoprotein subfractions and low-density lipoprotein peak particle size in patients with mixed hyperlipidemia.
Tribble DL; Farnier M; Macdonell G; Perevozskaya I; Davies MJ; Gumbiner B; Musliner TA
Metabolism; 2008 Jun; 57(6):796-801. PubMed ID: 18502262
[TBL] [Abstract][Full Text] [Related]
13. Structural peculiarities of the binding of very low density lipoproteins and low density lipoproteins to the LDL receptor in hypertriglyceridemia: role of apolipoprotein E.
Dergunov AD; Smirnova EA; Merched A; Visvikis S; Siest G; Yakushkin VV; Tsibulsky V
Biochim Biophys Acta; 2000 Feb; 1484(1):29-40. PubMed ID: 10685028
[TBL] [Abstract][Full Text] [Related]
14. Effects of niceritrol (pentaerythritol tetranicotinate) on plasma lipoprotein concentration: increment of high density lipoprotein(HDL) cholesterol and HDL-cholesterol/low density lipoprotein cholesterol ratio in hypo-high density lipoproteinemia.
Oida K; Nakai T; Tamai T; Kutsumi Y; Kobayashi T; Hayashi T; Yamada S; Takeda R
Artery; 1982; 10(4):266-85. PubMed ID: 7181672
[TBL] [Abstract][Full Text] [Related]
15. Atherogenic lipoprotein profile in families with and without history of early myocardial infarction.
Dobiásová M; Raslová K; Rauchová H; Vohnout B; Ptácková K; Frohlich J
Physiol Res; 2001; 50(1):1-8. PubMed ID: 11300220
[TBL] [Abstract][Full Text] [Related]
16. Analyzing of high-density lipoprotein subfractions and low-density lipoprotein subfractions in human serum with anion-exchange chromatography.
Hirowatari Y; Tsunoda Y; Ogura Y; Homma Y
Atherosclerosis; 2009 Jun; 204(2):e52-7. PubMed ID: 19091316
[TBL] [Abstract][Full Text] [Related]
17. The effect of nutritional habits on maternal-neonatal lipid and lipoprotein serum levels in three different ethnic groups.
Schulpis KH; Gavrili S; Vlachos G; Karikas GA; Michalakakou K; Demetriou E; Papassotiriou I
Ann Nutr Metab; 2006; 50(3):290-6. PubMed ID: 16508258
[TBL] [Abstract][Full Text] [Related]
18. Changes in plasma lipids with psychosocial stress are related to hypertension status and the norepinephrine stress response.
Wirtz PH; Ehlert U; Bärtschi C; Redwine LS; von Känel R
Metabolism; 2009 Jan; 58(1):30-7. PubMed ID: 19059528
[TBL] [Abstract][Full Text] [Related]
19. Effects of chlorthalidone and metoprolol alone or in combination (logroton) on blood pressure, lipids, lipoproteins and circulating plasma ANF levels in essential hypertension.
Bielmann P; Leduc G; Thibault G; Lepage J; Davignon J
Int J Clin Pharmacol Ther Toxicol; 1991 Dec; 29(12):479-85. PubMed ID: 1839902
[TBL] [Abstract][Full Text] [Related]
20. Relation between QT interval variability and cardiac sympathetic activity in hypertension.
Baumert M; Schlaich MP; Nalivaiko E; Lambert E; Sari CI; Kaye DM; Elser MD; Sanders P; Lambert G
Am J Physiol Heart Circ Physiol; 2011 Apr; 300(4):H1412-7. PubMed ID: 21257917
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
